Premium
Diversity, developmental regulation and distribution of murine PR55/B subunits of protein phosphatase 2A
Author(s) -
Schmidt Karsten,
Kins Stefan,
Schild Andreas,
Nitsch Roger M.,
Hemmings Brian A.,
Götz Jürgen
Publication year - 2002
Publication title -
european journal of neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.346
H-Index - 206
eISSN - 1460-9568
pISSN - 0953-816X
DOI - 10.1046/j.1460-9568.2002.02274.x
Subject(s) - protein phosphatase 2 , biology , protein subunit , gene isoform , northern blot , microbiology and biotechnology , genetics , gene , gene expression
Protein phosphatase (PP2A) 2A is a hetero‐trimeric holoenzyme that consists of a core dimer composed of a catalytic subunit that is tightly complexed with the scaffolding subunit PR65/A. This core dimer associates with variable regulatory subunits of the PR55/B, PR61/B′, PR72/B′′ and PR93/PR110/B′′′ families. As PP2A holoenzymes containing PR55/B have been shown to be involved in the pathogenesis of Alzheimer's disease, we characterized the PR55/B family with particular emphasis on its distribution and expression in the brain. We determined the genomic organization of all members of the PR55/B family and cloned their murine cDNAs. Thereby, two novel splice variants of PR55/Bβ were identified. In addition, Northern blot analysis revealed multiple transcripts for the different PR55 subunits, suggesting a higher variability within the PR55 family. In situ hybridization analysis revealed that all PR55/B subunits were widely expressed in the brain. PR55/Bα and Bβ protein expression varies significantly in areas of the brain affected by neurodegenerative diseases such as the hippocampus or cerebellum. At the cellular level, PR55/Bβ protein expression was confined to neurons, whereas PR55/Bα was also expressed in activated astrocytes indicating that the PR55 isoforms confer a different function to the holoenzyme complex. As PP2A dysfunction has been demonstrated to contribute to various human diseases, dissecting the PP2A holoenzyme and its particular function in different cell types will assist in the development of novel therapeutic strategies.